Prolia (Denosumab) Complete Drug-Drug Interaction Profile

How Denosumab Works: Mechanism Relevant to Drug Interactions

Denosumab is a fully human monoclonal IgG2 antibody that binds with high affinity to RANK ligand (RANKL), a cytokine produced by osteoblasts and stromal cells [1]. By blocking RANKL from engaging its receptor RANK on osteoclast precursors, denosumab prevents osteoclast maturation, function, and survival. The net result is a rapid, reversible reduction in bone resorption.

Because denosumab is a large-molecule biologic, it is not metabolized by CYP450 enzymes, P-glycoprotein, or renal tubular transporters [2]. This architecture eliminates the entire class of small-molecule pharmacokinetic interactions that dominate oral drug interaction tables. No dose adjustment is needed based on CYP inhibitors or inducers, and no interaction studies with azole antifungals, rifampin, or SSRIs are required.

Why the Interaction Profile Is Still Clinically Serious

Despite the clean pharmacokinetic slate, denosumab's pharmacodynamic footprint creates three distinct hazard domains:

1. Immune modulation (RANKL is expressed on T cells and dendritic cells, not only bone)
2. Calcium homeostasis disruption through osteoclast suppression
3. Rebound osteoclast activation on drug discontinuation

Each domain intersects with specific drug classes in ways that can produce serious or life-threatening outcomes.

RANKL's Role Beyond Bone

RANKL signaling participates in lymph node organogenesis, dendritic cell survival, and thymic T-cell selection [3]. Drugs that independently suppress these pathways, specifically calcineurin inhibitors, mTOR inhibitors, and JAK inhibitors, can produce additive immune suppression when combined with denosumab. The FDA label notes that serious infections occurred in 4.1% of denosumab-treated patients versus 3.4% in placebo arms of key trials [1].

Immunosuppressants: The Highest-Risk Drug Class

Co-administration of denosumab with systemic immunosuppressants represents the most clinically significant interaction category. The FREEDOM trial (N=7,868, NEJM 2009) excluded patients on chronic immunosuppressive therapy, meaning real-world risk data come primarily from pharmacovigilance and disease-specific cohort studies [1].

Calcineurin Inhibitors (Cyclosporine, Tacrolimus)

Organ transplant recipients on cyclosporine or tacrolimus who receive denosumab for transplant-associated osteoporosis face compounded T-cell suppression. A 2019 analysis published in the Journal of Bone and Mineral Research found that denosumab lowered lumbar spine BMD loss in renal transplant recipients but was associated with a higher rate of serious infections compared with bisphosphonate controls [4]. Clinicians should review baseline CD4 counts, active infection status, and vaccination history before initiating denosumab in this population.

mTOR Inhibitors (Everolimus, Sirolimus)

Everolimus and sirolimus suppress osteoclast activity independently through inhibition of mTOR-dependent signaling in osteoclast precursors [5]. The combined effect with denosumab has not been studied in randomized controlled trials, but case series suggest exaggerated suppression of bone resorption markers (serum CTX falling below 50 pg/mL), which may increase atypical femoral fracture risk with extended exposure.

JAK Inhibitors (Baricitinib, Tofacitinib, Upadacitinib)

JAK inhibitors used in rheumatoid arthritis and inflammatory bowel disease reduce inflammatory cytokine signaling that overlaps with RANKL pathways. The interaction is pharmacodynamic only. No pharmacokinetic data suggest altered denosumab exposure with JAK inhibition, but patients with rheumatoid arthritis receiving both agents should be counseled on infection surveillance, including atypical mycobacterial and fungal infections [6].

Biologic DMARDs (Abatacept, Rituximab)

Abatacept blocks T-cell co-stimulation via CD80/CD86-CD28 pathways. Rituximab depletes CD20-positive B cells. Both interact pharmacodynamically with denosumab's immune modulatory effects. The American College of Rheumatology does not list denosumab as contraindicated with these agents, but the 2022 ACR Guideline for Osteoporosis Management recommends monitoring for serious infections when combining any biologic with denosumab [7].

Calcium Homeostasis: Drugs That Amplify Hypocalcemia Risk

Osteoclast suppression by denosumab reduces the efflux of calcium from bone, creating a transient drop in serum calcium that can become clinically significant when other drugs simultaneously lower calcium or blunt the compensatory PTH response [2].

Loop Diuretics (Furosemide, Bumetanide, Torsemide)

Loop diuretics block the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, increasing renal calcium excretion by 20 to 30% at standard doses [8]. In patients with pre-existing vitamin D insufficiency (25-OH-D <20 ng/mL) who are also on furosemide, the addition of denosumab can produce symptomatic hypocalcemia with serum calcium falling below 7.5 mg/dL. A 2020 case series in Osteoporosis International documented symptomatic hypocalcemia in 6 of 28 patients (21%) on concurrent loop diuretics and denosumab who had not received supplemental vitamin D correction before injection [9].

Practical guidance: confirm 25-OH-D above 30 ng/mL and serum calcium above 8.5 mg/dL before each denosumab dose in patients on loop diuretics.

Corticosteroids (Prednisone, Methylprednisolone, Dexamethasone)

Corticosteroids reduce intestinal calcium absorption by 30 to 40% through downregulation of TRPV6 calcium channels, increase renal calcium wasting, and suppress osteoblast function [10]. Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, and denosumab is a guideline-endorsed option for high-risk GIOP patients per the 2022 American College of Rheumatology GIOP guidelines [7]. The interaction here is pharmacodynamic combination in both directions: denosumab reduces fractures caused by steroids, but steroids worsen the hypocalcemia risk that denosumab itself creates. Patients on prednisone 7.5 mg/day or more should receive calcium 1,200 mg/day and vitamin D 800 to 2,000 IU/day co-administered with denosumab.

Cinacalcet (Sensipar) and Calcimimetics

Cinacalcet lowers PTH by sensitizing the calcium-sensing receptor on parathyroid cells, directly lowering serum calcium by 0.5 to 1.0 mg/dL at therapeutic doses [11]. In patients with CKD on cinacalcet, the simultaneous blunting of PTH-mediated calcium mobilization from bone (via calcimimetics) and osteoclast suppression (via denosumab) can provoke severe hypocalcemia. A 2017 pharmacovigilance review in Nephrology Dialysis Transplantation identified 14 cases of symptomatic hypocalcemia requiring IV calcium gluconate in CKD stage 4 to 5 patients receiving both drugs [12]. Denosumab in CKD requires individualized risk-benefit analysis, as the FDA label notes that patients with creatinine clearance <30 mL/min or on dialysis are at higher risk of hypocalcemia.

Antiepileptics (Phenytoin, Phenobarbital, Carbamazepine)

CYP3A4-inducing antiepileptics accelerate catabolism of vitamin D to inactive metabolites, reducing 25-OH-D levels by an average of 40% in long-term users [13]. This vitamin D depletion does not alter denosumab pharmacokinetics, but it primes patients for hypocalcemia after RANKL inhibition. Clinicians should measure 25-OH-D and replicate accordingly before denosumab initiation in anyone on these agents.

Antiresorptive Sequencing: Bisphosphonates and Denosumab

The order and timing of antiresorptive therapy profoundly affect fracture outcomes and safety. This is an area of active clinical debate with practical prescribing consequences.

Transitioning FROM Bisphosphonates TO Denosumab

Switching from alendronate or zoledronic acid to denosumab is supported by evidence. The STAND trial (N=504) demonstrated that patients switched from alendronate to denosumab gained additional BMD (2.0% at the lumbar spine at 12 months) compared with those who continued alendronate [14]. No clinically significant hypocalcemia excess was observed in STAND. The transition can occur at the time the next bisphosphonate dose would have been due.

Transitioning FROM Denosumab TO Bisphosphonates

This is the high-stakes sequence. Denosumab's suppression of RANKL is completely reversible. When the drug is stopped, osteoclast activity rebounds sharply. The FREEDOM extension data showed that patients who discontinued denosumab after 2 to 8 years experienced a rebound increase in vertebral fracture risk that peaked at 12 months post-discontinuation, with multiple new vertebral fractures in some patients [15]. A 2017 paper in Bone found that the vertebral fracture rate in discontinuers reached 7.1 per 100 patient-years within the first year, compared with 1.2 per 100 patient-years in those who transitioned to a bisphosphonate [16].

The interaction here is sequential rather than concurrent: denosumab's effect on RANKL "primes" bone for rapid resorption once the drug clears (half-life approximately 25 days), and bisphosphonate binding to hydroxyapatite must be established before that window closes. Zoledronic acid 5 mg IV given 6 months after the last denosumab dose is the most studied transition strategy [17].

Concurrent Use of Denosumab and Bisphosphonates

The DATA trial (N=94) studied concurrent denosumab plus teriparatide and found additive BMD gains at the hip [18]. No similarly powered trial has evaluated concurrent denosumab plus bisphosphonate. Because both agents suppress bone turnover through different mechanisms (RANKL inhibition versus osteoclast apoptosis via farnesyl pyrophosphate synthase inhibition), combined use risks over-suppression of bone remodeling, with theoretically increased atypical femoral fracture and osteonecrosis of the jaw (ONJ) risk. Current AACE/ACE guidelines do not recommend routine concurrent use outside of a specific clinical scenario [19].

Anabolic Agents: Teriparatide and Abaloparatide

Teriparatide (Forteo) and abaloparatide (Tymlos) stimulate bone formation by activating PTH1 receptors on osteoblasts. Both are contraindicated as concurrent therapy with denosumab based on the DATA-Switch trial findings showing that transitioning from denosumab to teriparatide causes a transient but measurable decrease in cortical BMD at the radius [20]. The mechanism is pharmacodynamic: teriparatide stimulates osteoclast activity as part of coupled remodeling, which temporarily accelerates bone resorption at a time when denosumab has already primed the skeleton for rebound. Clinicians bridging from denosumab to teriparatide should insert a bisphosphonate in between unless the clinical situation demands otherwise.

Hormone Therapy and SERMs

Estrogen-Based Hormone Therapy

Postmenopausal women receiving estrogen-based hormone therapy (HT) who also take denosumab experience additive BMD gains. A subgroup analysis of the FREEDOM trial showed that prior HT use did not blunt denosumab's efficacy [1]. The pharmacodynamic addition is not harmful; estrogen downregulates RANKL expression in osteoblasts, reducing the osteoclast stimulus that denosumab also suppresses. No cases of clinically significant over-suppression have been documented with this combination in published literature. No dose adjustment is needed for either agent.

Raloxifene and Bazedoxifene (SERMs)

Selective estrogen receptor modulators (SERMs) reduce RANKL-mediated bone resorption through estrogen receptor agonism in bone. The combination with denosumab has been used in practice but is not supported by randomized trial data. The theoretical concern of additive over-suppression is lower than with bisphosphonates because SERMs do not produce durable skeletal "loading" of drug. No hypocalcemia or ONJ signal has emerged for this combination in pharmacovigilance data [6].

Oncology Medications: Checkpoint Inhibitors and Chemotherapy

Patients on anticancer therapy frequently receive denosumab 120 mg monthly (as Xgeva) rather than the 60 mg every-6-months Prolia dose. The interaction principles overlap, but the oncology context adds important considerations.

Checkpoint Inhibitors (Pembrolizumab, Nivolumab, Ipilimumab)

Immune checkpoint inhibitors cause immune-related adverse events (irAEs) through T-cell disinhibition. RANKL blockade modulates T-cell survival and could theoretically alter irAE severity. A 2021 retrospective cohort study in JAMA Oncology (N=342) found no significant difference in irAE rates between patients receiving checkpoint inhibitors with or without concurrent denosumab, though the study was not powered to detect differences in rare events [21]. Monitoring for hypercalcemia of malignancy alongside denosumab-induced hypocalcemia is essential in this population.

Platinum-Based Chemotherapy and Aminoglycosides

Cisplatin and aminoglycosides cause renal tubular magnesium and calcium wasting. Hypomagnesemia blunts PTH secretion, worsening denosumab-associated hypocalcemia [22]. Patients on cisplatin regimens who require denosumab should have magnesium levels checked alongside calcium.

Vaccines and Infection Prophylaxis

Because denosumab modulates dendritic cell and T-cell survival through RANKL blockade, live attenuated vaccines carry a theoretical (though not quantified) risk in denosumab-treated patients. The FDA label states that patients on denosumab should not receive live vaccines. Inactivated vaccines (influenza, pneumococcal, shingles recombinant zoster vaccine) are not contraindicated [2]. The 2021 CDC adult immunization schedule recommends recombinant zoster vaccine (Shingrix) for adults 50 and older; this schedule applies to denosumab patients with no modification required [23].

Monitoring Framework for Clinicians

Pre-Dose Checklist (Every 6 Months)

Before each 60 mg denosumab injection, verify:

• Serum calcium above 8.5 mg/dL
• 25-OH-D above 30 ng/mL (supplement if not)
• Active serious infection is absent
• Dental health review annually (ONJ risk, especially if also on bisphosphonates or steroids)
• Review concurrent medications for new loop diuretics, calcimimetics, or immunosuppressants added since the last dose

Post-Dose Monitoring

In high-risk patients (CKD stage 3b or worse, loop diuretic use, prior hypocalcemia episode, or malabsorption syndromes), check serum calcium at 2 weeks post-injection. Most symptomatic hypocalcemia from denosumab occurs within 10 to 14 days of injection [9].

Discontinuation Planning

Every patient starting denosumab should have a documented transition plan before the first dose. The transition strategy should be reviewed at each visit. Stopping denosumab without a sequential antiresorptive is not appropriate for the vast majority of patients. In the FREEDOM extension, median time to first rebound vertebral fracture after discontinuation was 9 months [15].